The company said it expects to begin offering its Envisia classifier, for use in idiopathic pulmonary fibrosis diagnosis, to customers in 2021 as a kit-based test that runs on the nCounter system. As part of the deal, Veracyte also acquired NanoString Prosigna breast cancer prognostic test and in-development LymphMark lymphoma subtyping assay to expand its oncology portfolio.
Veracyte said it expects to realize a modest revenue contribution through the transaction of $6 million to $8 million in 2020, with a neutral impact to cash flow from the current business.
Price: 26.26, Change: -0.93, Percent Change: -3.54
|Q4, 2019, and 2020 Earnings Estimates for WellCare H...|
|2019, 2020 Earnings Estimates for Wabash National Sc...|
|Forecast for Valero Energy's Q4 and Full Year Earnin...|
|Analysts Scale Back VF Corp's Q4, 2020, and 2021 Ear...|
|Univest Financial's 2020, 2021, and Q1 Earnings Esti...|